A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 188,830 shares of AZN stock, worth $12.7 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
188,830
Previous 178,868 5.57%
Holding current value
$12.7 Million
Previous $13.9 Million 5.48%
% of portfolio
0.02%
Previous 0.02%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$76.67 - $87.62 $763,786 - $872,870
9,962 Added 5.57%
188,830 $14.7 Million
Q2 2024

Jul 19, 2024

BUY
$66.81 - $80.83 $180,787 - $218,725
2,706 Added 1.54%
178,868 $13.9 Million
Q1 2024

Apr 22, 2024

BUY
$61.03 - $69.57 $802,605 - $914,915
13,151 Added 8.07%
176,162 $11.9 Million
Q4 2023

Jan 16, 2024

BUY
$61.89 - $69.28 $3.07 Million - $3.43 Million
49,541 Added 43.66%
163,011 $11 Million
Q3 2023

Oct 24, 2023

SELL
$64.85 - $71.7 $121,723 - $134,580
-1,877 Reduced 1.63%
113,470 $7.68 Million
Q2 2023

Jul 25, 2023

SELL
$69.91 - $75.81 $344,376 - $373,440
-4,926 Reduced 4.1%
115,347 $8.26 Million
Q1 2023

Apr 14, 2023

BUY
$63.15 - $71.6 $308,045 - $349,264
4,878 Added 4.23%
120,273 $8.35 Million
Q4 2022

Feb 08, 2023

SELL
$54.21 - $70.44 $214,725 - $279,012
-3,961 Reduced 3.32%
115,395 $7.82 Million
Q3 2022

Oct 25, 2022

SELL
$53.02 - $135.75 $8,642 - $22,127
-163 Reduced 0.14%
119,356 $6.55 Million
Q2 2022

Aug 12, 2022

SELL
$59.26 - $71.14 $77,926 - $93,549
-1,315 Reduced 1.09%
119,519 $7.9 Million
Q1 2022

May 11, 2022

SELL
$55.72 - $67.12 $2.02 Million - $2.43 Million
-36,259 Reduced 23.08%
120,834 $8.02 Million
Q4 2021

Feb 08, 2022

SELL
$54.02 - $63.83 $89,781 - $106,085
-1,662 Reduced 1.05%
157,093 $9.15 Million
Q3 2021

Nov 02, 2021

BUY
$55.56 - $60.79 $3.88 Million - $4.25 Million
69,872 Added 78.61%
158,755 $9.54 Million
Q2 2021

Aug 11, 2021

SELL
$48.42 - $60.18 $511,557 - $635,801
-10,565 Reduced 10.62%
88,883 $5.32 Million
Q1 2021

May 14, 2021

SELL
$47.16 - $54.44 $3.2 Million - $3.69 Million
-67,781 Reduced 40.53%
99,448 $4.95 Million
Q4 2020

Feb 12, 2021

SELL
$48.52 - $58.02 $78,747 - $94,166
-1,623 Reduced 0.96%
167,229 $8.36 Million
Q3 2020

Nov 04, 2020

BUY
$53.07 - $61.1 $3.78 Million - $4.35 Million
71,243 Added 72.99%
168,852 $9.25 Million
Q2 2020

Jul 17, 2020

SELL
$43.1 - $55.31 $1.1 Million - $1.41 Million
-25,463 Reduced 20.69%
97,609 $5.16 Million
Q1 2020

Apr 21, 2020

SELL
$37.79 - $51.33 $484,052 - $657,485
-12,809 Reduced 9.43%
123,072 $5.5 Million
Q4 2019

Feb 12, 2020

BUY
$42.46 - $50.46 $1.62 Million - $1.93 Million
38,188 Added 39.09%
135,881 $6.78 Million
Q3 2019

Nov 07, 2019

SELL
$40.12 - $45.47 $718,308 - $814,094
-17,904 Reduced 15.49%
97,693 $4.35 Million
Q2 2019

Aug 06, 2019

SELL
$37.28 - $41.68 $371,196 - $415,007
-9,957 Reduced 7.93%
115,597 $4.77 Million
Q1 2019

May 06, 2019

SELL
$35.49 - $43.02 $227,242 - $275,457
-6,403 Reduced 4.85%
125,554 $5.08 Million
Q4 2018

Feb 11, 2019

SELL
$36.86 - $41.49 $927,545 - $1.04 Million
-25,164 Reduced 16.02%
131,957 $5.01 Million
Q3 2018

Nov 14, 2018

SELL
$34.76 - $39.72 $314,717 - $359,624
-9,054 Reduced 5.45%
157,121 $6.22 Million
Q2 2018

Jul 30, 2018

SELL
$34.55 - $37.05 $1.26 Million - $1.35 Million
-36,456 Reduced 17.99%
166,175 $5.83 Million
Q1 2018

Apr 16, 2018

BUY
$32.97 - $36.63 $1.03 Million - $1.14 Million
31,249 Added 18.23%
202,631 $7.09 Million
Q4 2017

Feb 09, 2018

BUY
$32.09 - $34.78 $1.85 Million - $2.01 Million
57,669 Added 50.71%
171,382 $5.95 Million
Q3 2017

Oct 26, 2017

BUY
$28.96 - $34.0 $500,168 - $587,214
17,271 Added 17.91%
113,713 $3.85 Million
Q2 2017

Aug 15, 2017

BUY
N/A
96,442
96,442 $3.29 Million

Others Institutions Holding AZN

About ASTRAZENECA PLC


  • Ticker AZN
  • Exchange OTC
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 3,099,020,032
  • Market Cap $208B
  • Description
  • AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...
More about AZN
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.